相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
Weili Xue et al.
ONCOTARGETS AND THERAPY (2019)
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
Chin-King Looi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Alexios Matikas et al.
CLINICAL CANCER RESEARCH (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Xiangfeng Shen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer
Marra Jai Aghajani et al.
ENDOCRINE CONNECTIONS (2019)
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorena Incorvaia et al.
ADVANCES IN THERAPY (2019)
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
Kiyohiro Ando et al.
ANTICANCER RESEARCH (2019)
LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat et al.
ANNALS OF ONCOLOGY (2019)
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression
Tsunehiko Shigemori et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel et al.
LANCET ONCOLOGY (2019)
Prognostic value of PD-L1 expression in patients with pancreatic cancer A PRISMA-compliant meta-analysis
Ying Hu et al.
MEDICINE (2019)
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
Maria J. Disselhorst et al.
LANCET RESPIRATORY MEDICINE (2019)
Eosinophils: The unsung heroes in cancer?
Gilda Varricchi et al.
ONCOIMMUNOLOGY (2018)
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
Yusuke Okuma et al.
CLINICAL LUNG CANCER (2018)
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
Masahiro Takeuchi et al.
IMMUNOLOGY LETTERS (2018)
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
Luana Calabro et al.
LANCET RESPIRATORY MEDICINE (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Xian Shen et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio et al.
LANCET ONCOLOGY (2017)
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Yusuke Okuma et al.
LUNG CANCER (2017)
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Xinxin Zhu et al.
ONCOTARGET (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y. Xu-Monette et al.
FRONTIERS IN IMMUNOLOGY (2017)
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Beyond melanoma: inhibiting the PD-1/PDL-1 pathway in solid tumors
Ryan Gentzler et al.
IMMUNOTHERAPY (2016)
Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
Naoki Takahashi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
Hyerim Ha et al.
ONCOTARGET (2016)
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Francesco Passiglia et al.
ONCOTARGET (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
Liang Wang et al.
ONCOTARGET (2015)
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
D. Rossille et al.
LEUKEMIA (2014)
Soluble B7-H1: Differences in production between dendritic cells and T cells
Xavier Frigola et al.
IMMUNOLOGY LETTERS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
Xavier Frigola et al.
CLINICAL CANCER RESEARCH (2011)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
分享论文
